Shipping to France We Offer Worldwide Shipping
Login Wishlist

D-Glucosamine sulfate

$48

  • Brand : BIOFRON

  • Catalogue Number : AV-H12036

  • Specification : 98%

  • CAS number : 29031-19-4

  • Formula : C6H13NO5.H2SO4

  • Molecular Weight : 277.25

  • PUBCHEM ID : 115046

  • Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-H12036

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

277.25

Appearance

White crystalline powder

Botanical Source

Structure Type

Category

Standards;Natural Pytochemical;API

SMILES

C(C(C(C(C(C=O)N)O)O)O)O.OS(=O)(=O)O

Synonyms

D-Glucose, 2-amino-2-deoxy-, sulfate (1:1)/D-Glucosamine sulfate/2-Amino-2-deoxy-D-glucose sulfate (1:1)

IUPAC Name

(2R,3R,4S,5R)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid

Applications

Density

1.563g/cm3

Solubility

Flash Point

225.9ºC

Boiling Point

449.9ºC at 760mmHg

Melting Point

176°C

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:29031-19-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

17515291

Abstract

The pharmacological treatment of osteoarthritis is traditionally accomplished with nonspecific symptomatic agents, which are generally effective only for acute symptom relief. Compounds are under investigation that might exert specific effects on osteoarthritis pathogenesis and thus induce at least a similar short-term symptomatic effect, but also control disease progression in the long term. Glucosamine sulphate (CAS 29031-19-4) reverses the proinflammatory and joint-degenerating effects of interleukin-1 by inhibiting the cytokine intracellular pathway. Clinical trials with the crystalline glucosamine sulphate formulation (CGS; dona) approved as a medicinal drug, predominantly used at the oral dose of 1,500 mg once daily, demonstrated a specific symptom-modifying effect on knee osteoarthritis over short- and long-term treatment courses. Two 3-year trials suggested that the drug also has joint structure-modifying properties and, therefore, might be useful as a disease-modifying agent in osteoarthritis.

Title

[Therapy of osteoarthritis crystalline glucosamine sulphate/a review of the clinical effcacy].

Author

Heisel J1, Forster KK.

Publish date

2007

PMID

9638313

Abstract

A double-blind therapeutic investigation was performed on 178 Chinese patients suffering from osteoarthritis of the knee randomized into two groups, one treated for 4 weeks with glucosamine sulfate (GS, CAS 29031-19-4, Viartril-S) at the daily dose of 1,500 mg and the other with ibuprofen (IBU, CAS 15687-27-1) at the daily dose of 1,200 mg. Knee pain at rest, at movement and at pressure, knee swelling, improvement and therapeutic utility as well as adverse events and drop-outs were recorded after 2 and 4 weeks of treatment. The variables were recorded also after 2 weeks of treatment discontinuation in order to appreciate the remnant therapeutic effect. Both GS and IBU significantly reduced the symptoms of osteoarthritis with the trend of GS to be more effective. After 2 weeks of drug discontinuation there was a remnant therapeutic effect in both groups, with the trend to be more pronounced in the GS group. GS was significantly better tolerated than IBU, as shown by the adverse drug reactions (6% in the patients of the GS group and 16% in the IBU group–p = 0.02) and by the drug-related drop-outs (0% of the patients in the GS group and 10% in the IBU group–p = 0.0017). The better tolerability of GS is explained by its mode of action, because GS specifically curbs the pathogenic mechanisms of osteoarthritis and does not inhibit the cyclo-oxygenases as the non-steroidal anti-inflammatory drugs (NSAIDs) do, with the consequent anti-inflammatory analgesic activities but also with the several adverse reactions due to this not targeted effect. The present study confirms that GS is a selective drug for osteoarthritis, as effective on the symptoms of the disease as NSAIDs but significantly better tolerated. For these properties GS seems particularly indicated in the long-term treatments needed in osteoarthritis.

Title

Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis.

Author

Qiu GX1, Gao SN, Giacovelli G, Rovati L, Setnikar I.

Publish date

1998 May

PMID

8135881

Abstract

Glucosamine sulfate (Dona, CAS 29031-19-4) is a drug used in the treatment of osteoarthritis. When orally given, it is more effective than placebo and at least as effective as non-steroidal anti-inflammatory drugs in relieving osteoarthritis symptoms. The aim of this multicentre, randomised, placebo-controlled, double-blind, parallel-group study was to assess the efficacy and safety of glucosamine sulfate intramuscularly given on the same parameters. 155 out-patients with knee osteoarthritis (Lequesne’s criteria), radiological stage between I and III, Lequesne’s severity index of at least 4 points and symptoms for at least 6 months, were treated with i.m. glucosamine sulfate (or placebo) 400 mg twice a week for 6 weeks. Clinic visits were performed at enrollment, after a 2-week baseline, at weekly intervals during treatment and 2 weeks after drug discontinuation. Responders to treatment were considered those patients with a reduction of at least 3 points in the Lequesne index, together with a positive overall judgement by the investigator. The Lequesne index was slightly over 10 points in average in both groups at the beginning of treatment. A significant decrease in the index was observed for glucosamine compared to placebo (3.3 vs. 2.0 points in average, respectively; p < 0.05, Student's t-test). The responder rate in the evaluable patients was 55% with glucosamine (n = 73) and only 33% (n = 69) with placebo (p = 0.012, Fisher's Exact Test). According to the intention-to-treat approach, considering also drop-outs, these proportions were 51% vs. 30% (p = 0.015).(ABSTRACT TRUNCATED AT 250 WORDS).

Title

Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study.

Author

Reichelt A1, Forster KK, Fischer M, Rovati LC, Setnikar I.

Publish date

1994 Jan